Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 67877-064

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 67877-064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine-4mg-1 (Fesoterodine 4mg 1)

Each tablet of ASCEnD contains 4mg of fesoterodine fumarate, and is film-coated. The usual dosage is not available, and prescribing information must be adhered to. These extended-release tablets must be stored in an unvarnished area between 15°C and 30°C, protected from moisture. They measure 45x20mm (LxH). This medication is manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories LLC. A patient information leaflet should be included with the package. This medication is only available via prescription.*

FDA Label Image

Fesoterodine-8mg-1 (Fesoterodine 8mg 1)

This text appears to be a combination of a description of a medication called Fesoterodine Fumarate and packaging instructions. The medication comes in a form of extended-release, film-coated tablets that contain 8mg of Fesoterodine Fumarate. The tablets should be stored between 15 and 30 degrees Celsius and protected from moisture. A pharmacist should dispense the medication with an information leaflet for the patient. The manufacturer is Alkem Laboratories Ltd. and the medication is distributed by Ascend Laboratories LLC in Parsippany, NJ.*

FDA Label Image

Fesoterodine-fig1.jpg (Fesoterodine Fig1)

FDA Label Image

Fesoterodine-fig2.jpg (Fesoterodine Fig2)

The text describes a graph or figure showing the change in urge incontinence episodes per 24 hours over the course of several weeks. The figure includes a comparison between two treatments, one labeled as "placebo" and the other as "fesoterodine fumarate." The mean change from baseline is given for each treatment. No further information is available.*

FDA Label Image

Fesoterodine-fig3.jpg (Fesoterodine Fig3)

The text is presenting a figure titled “Change in Number of Micturitions per 24 h (Study 2)”. The figure consists of a graph with the X-axis representing the weeks of the study and the Y-axis representing the number of micturitions per 24 hours. However, due to errors, the drug names and dosages cannot be accurately determined from the provided text.*

FDA Label Image

Fesoterodine-fig4.jpg (Fesoterodine Fig4)

The text includes a figure labeled "Figure 4" representing the change in Urge Incontinence Episodes per 24 h over time (Weeks 0, 2, and 8) for two groups of patients: one group receiving Fesoterodine Fumarate ER Tablets (n=228) and the other group receiving a placebo (n=218).*

FDA Label Image

Fesoterodine-str (Fesoterodine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.